Status:

NOT_YET_RECRUITING

Digital Diet and Exercise Intervention to Reduce Liver Fibrosis in Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)

Lead Sponsor:

St. George's Hospital, London

Conditions:

Metabolic Dysfunction-Associated Steatotic Liver Disease

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

Study Title: Digital Diet and Exercise Intervention to Reduce Liver Fibrosis in Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Randomized Controlled Trial (D-FIB-MASLD) Objective...

Eligibility Criteria

Inclusion

  • Adults 18 years and over
  • Diagnosis of MASLD made by a hepatologist
  • Vibration-Controlled Transient Elastography (VCTE) (FibroScan) liver stiffness measurement (LSM) 8 kPa and above
  • Able to provide written consent
  • Own a smartphone with data plan

Exclusion

  • Alcohol consumption \>14 units/week
  • BMI \>40
  • Liver disease due to: Alcohol including MASLD with increased alcohol intake (MetALD), Any viral hepatitis, Autoimmune and cholestatic aetiologies including, but not limited to, primary biliary cholangitis and primary sclerosing cholangitis, Hereditary aetiologies including, but not limited to, haemachromatosis, Wilson's disease, alpha-1-antitrypsin deficiency
  • Currently under investigation for cancer or receiving treatment for active cancer
  • Myocardial infarction within last 6 months or uncontrolled cardiovascular disease
  • Pregnant or planning
  • Currently or due to be taking any of the following drugs: GLP-1/GIP agonists, Systemic high dose corticosteroids for \>6 weeks, Tamoxifen, Amiodarone, Methotrexate, Lomitapide, Valproate, Irinotecan, 5-Fluoruracil
  • Currently using or enrolled in any other lifestyle intervention application or weight loss programme
  • Undergone or due to undergo bariatric surgery including bariatric endoscopic procedures
  • Any other intercurrent illness that is either life-threatening or of clinical significance such that it might limit compliance with study procedures, in the Investigator's opinion

Key Trial Info

Start Date :

May 1 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 1 2027

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT06920316

Start Date

May 1 2025

End Date

September 1 2027

Last Update

April 9 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

St George's University Hospitals NHS Foundation Trust

London, London, United Kingdom, SW170QT

Digital Diet and Exercise Intervention to Reduce Liver Fibrosis in Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) | DecenTrialz